Brought to you by 
Bridge Biotherapeutics raises $10mm in Series A funding
20 Sep 2017
Executive Summary
Bridge Biotherapeutics (inflammatory diseases) raised $10mm in a Series A round from LB Investment and KB Investment. The company was founded in 2015 and is focusing on commercializing compounds developed or discovered by third parties and is currently working on BBT4401, an anti-inflammatory agent discovered by Sungkyunkwan University's professor Park Seok-hee and his research team.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Bridge Biotherapeutics raises $10mm in Series A funding
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice